8月7日,康泰生物开盘涨停。昨日公司公告称,阿斯利康与康泰生物就新冠疫苗达成授权合作,康泰生物将确保在年底前达到至少1亿剂年产能。
“特别声明:以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布,本平台仅提供信息存储空间服务。
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”